Alexander E. Perl
Impact in
- Hematology top 0.05%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Cancer Research top 2%
- Cancer, Hypoxia, and Metabolism
Papers in
- Hematology 172
- Acute Myeloid Leukemia Research 155
- Hematopoietic Stem Cell Transplantation 12
- Multiple Myeloma Research and Treatments 5
- Chronic Myeloid Leukemia Treatments 4
-
- Frailty in Older Adults 4
- Co-authors
- Martin P Carroll (41 shared papers)Mark J. Levis (40 shared papers)Ross L. Levine (4 shared papers)Craig B. Thompson (2 shared papers)Omar Ibrahim Abdel-Wahab (3 shared papers)Catherine Choy Smith (23 shared papers)Shin-San Michael Su (1 shared paper)Kim A. Sharp (1 shared paper)
- Journals
- Blood (67 papers)Blood Advances (18 papers)Transplantation and Cellular Therapy (12 papers)American Journal of Hematology (7 papers)Journal of Clinical Oncology (7 papers)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Alexander E. Perl
194 papers receiving 12.2k citations
Alexander E. Perl's Hit Papers
Peers
Comparison fields: 5 of 112
- Hematology 8.1k
- Cancer Research 898
- Genetics 504
- Oncology 767
- Molecular Biology 1.4k
Countries citing papers authored by Alexander E. Perl
This map shows the geographic impact of Alexander E. Perl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander E. Perl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander E. Perl more than expected).
Fields of papers citing papers by Alexander E. Perl
This network shows the impact of papers produced by Alexander E. Perl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander E. Perl. The network helps show where Alexander E. Perl may publish in the future.
Co-authors
The 25 scholars most cited alongside Alexander E. Perl, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 202 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate Hit paper breakdown → | 2010 | 1706 |
| 2 | Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML Hit paper breakdown → | 2019 | 994 |
| 3 | Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia Hit paper breakdown → | 2012 | 638 |
| 4 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study Hit paper breakdown → | 2017 | 416 |
| 5 | Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2019 | 387 |
| 6 | 2012 | 357 | |
| 7 | Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2019 | 351 |
| 8 | 2011 | 344 | |
| 9 | Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia Hit paper breakdown → | 2019 | 341 |
| 10 | Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia Hit paper breakdown → | 2016 | 307 |
| 11 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 268 |
| 12 | NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021 Hit paper breakdown → | 2021 | 236 |
| 13 | 2019 | 226 | |
| 14 | 2018 | 222 | |
| 15 | 2014 | 192 | |
| 16 | 2005 | 190 | |
| 17 | 2013 | 174 | |
| 18 | 2010 | 158 | |
| 19 | 2015 | 157 | |
| 20 | Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Hit paper breakdown → | 2022 | 153 |
About Alexander E. Perl
Alexander E. Perl is a scholar working on Hematology, Geriatrics and Gerontology, Public Health, Environmental and Occupational Health, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 202 papers that have together received 12.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (155 papers), Hematopoietic Stem Cell Transplantation (12 papers), Acute Lymphoblastic Leukemia research (10 papers), Radiopharmaceutical Chemistry and Applications (5 papers), Multiple Myeloma Research and Treatments (5 papers), Retinoids in leukemia and cellular processes (5 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Frailty in Older Adults (4 papers). The work is most often cited by research in Hematology (8.1k citations), Cancer Research (898 citations), Genetics (504 citations), Oncology (767 citations) and Molecular Biology (1.4k citations). Alexander E. Perl has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Martin P Carroll, Mark J. Levis, Ross L. Levine, Craig B. Thompson, Omar Ibrahim Abdel-Wahab, Catherine Choy Smith, Shin-San Michael Su, Kim A. Sharp, Justin R. Cross and Cyrus V. Hedvat. Their work appears in journals such as Blood, Blood Advances, Transplantation and Cellular Therapy, American Journal of Hematology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.